Electroconvulsive therapy for super refractory status epilepticus: A scoping review
Epilepsia · 2025-08 · 66 (8) · 2657-2668
DOI: 10.1111/epi.18432 ↗Kurz gefasst
Scoping Review in der Zeitschrift Epilepsia, online erschienen am 02.05.2025. Verfasst von Delaney K Dowd und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics (Neurology), University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Electroconvulsive Therapy, Status Epilepticus, Drug Resistant Epilepsy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Objective
Status epilepticus (SE) is a neurologic emergency. Although evidence‐based treatments exist for SE, treatment of refractory status epilepticus (RSE) and super refractory status epilepticus (SRSE) lacks evidence. Electroconvulsive therapy (ECT) is safe and efficacious when used to treat psychiatric disorders. Seizure control attributed to ECT in the setting of SRSE has been reported in case reports and case series. The objective of this scoping review was to understand the current knowledge regarding the safety and efficacy of ECT in aborting SRSE in the adult and pediatric populations.
Methods
This scoping review was designed based on guidelines from the Joanna Briggs Institute (JBI) and the Preferred Reporting Items for Systematic reviews and Meta‐Analyses extension for Scoping Reviews (PRISMA‐ScR) checklist. Databases were searched to identify relevant studies, which were independently appraised by reviewers. Peer‐reviewed studies with focus on patients who were treated with ECT for SRSE were included. Patient demographic, ECT course, and clinical outcome data were collated in a prespecified proforma.
Results
Data were extracted from 16 studies, which included a combined 40 patients. Ages were unknown for eight patients. Of the patients whose ages were known, more pediatric patients than adults were previously healthy, and seizure etiology differed between these two subgroups. SE was aborted in 80% of adult and 100% of pediatric patients. One adverse effect related to ECT was reported. Seizure recurrence, new epilepsy diagnoses, technology dependence, and death were common. Significance Differences between adult and pediatric patients who are treated with electroconvulsive therapy (ECT) for SRSE could reflect a combination of factors, including logistical and regulatory barriers that limit use of ECT in intensive care units (ICUs). Prospective, randomized controlled trials are needed to fully understand the risks vs benefits of ECT for SRSE compared to other treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics (Neurology), University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pediatrics (Neurology and Epilepsy), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Galter Health Sciences Library, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
ORCID-Profile: Delaney K Dowd, Pooja D Shah
Zitieren
APA
Dowd, D. K., Nunes, D., Shah, P. D., & Pardo, A. C. (2025). Electroconvulsive therapy for super refractory status epilepticus: A scoping review. Epilepsia, 66(8), 2657-2668. https://doi.org/10.1111/epi.18432
Vancouver
Dowd DK, Nunes D, Shah PD, Pardo AC. Electroconvulsive therapy for super refractory status epilepticus: A scoping review. Epilepsia. 2025;66(8):2657-2668. doi:10.1111/epi.18432
BibTeX
@article{Dowd2025,
author = {Dowd, Delaney K and Nunes, Denise and Shah, Pooja D and Pardo, Andrea C},
title = {Electroconvulsive therapy for super refractory status epilepticus: A scoping review},
journal = {Epilepsia},
year = {2025},
volume = {66},
number = {8},
pages = {2657--2668},
doi = {10.1111/epi.18432}
}
EUVIMED